Drugs / Hyperpolarized 129 Xenon
Hyperpolarized 129 Xenon
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT02748798 | Nov 2020 → Oct 2021 | asbestosis, asthma, bronchiectasis, common cold +9 | Thunder Bay Regional Health Research Institute | Terminated | No outcome recorded |
| Phase 0 | NCT02638519 | Jun 2016 → Apr 2022 | Alzheimer disease | Thunder Bay Regional Health Research Institute | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02316379 | Feb 2015 → Aug 2030 expected | respiratory system disorder | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02272049 | Dec 2014 → Dec 2028 expected | respiratory system disorder | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07046910 | Apr 2019 → Mar 2029 expected | transplant rejection | University of Virginia | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperpolarized 129 Xenon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02272049 ↗ |
| Known as | HP 129Xe | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02748798 ↗ |
| Known as | Hyperpolarized Xenon129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07046910 ↗ |
| Modality | Diagnostic / imaging agent | “Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults” NCT02272049 ↗ |
| Route | Inhaled | “Subject will inhale hyperpolarized xenon gas” NCT02272049 ↗ |